Find therapies in clinical trials near you – page 76

Study on the Effectiveness and Safety of CAM2029 Compared to Octreotide and Lanreotide in Patients with Gastroenteropancreatic Neuroendocrine Tumors

Study on the Effectiveness and Safety of CAM2029 Compared to Octreotide and Lanreotide in Patients with Gastroenteropancreatic Neuroendocrine Tumors

Study of Pembrolizumab, MK-4830, and Chemotherapy for Patients with High-Grade Serous Ovarian Cancer

Study of Pembrolizumab, MK-4830, and Chemotherapy for Patients with High-Grade Serous Ovarian Cancer

Study on MK-6194 for Treating Adults with Non-Segmental Vitiligo

Study on MK-6194 for Treating Adults with Non-Segmental Vitiligo

Study of Pembrolizumab with Drug Combination for Patients with Advanced Non-Small Cell Lung Cancer

Study of Pembrolizumab with Drug Combination for Patients with Advanced Non-Small Cell Lung Cancer

Study on Andexanet Alfa for Patients on Factor Xa Inhibitors (Apixaban, Rivaroxaban, Edoxaban) Needing Urgent Surgery to Reduce Bleeding Risk

Study to Test Pembrolizumab, MK-4830, and MK-0482 in Patients with Advanced Non-Small Cell Lung Cancer Who Have Not Received Prior Treatment

Study to Test Pembrolizumab, MK-4830, and MK-0482 in Patients with Advanced Non-Small Cell Lung Cancer Who Have Not Received Prior Treatment

Study of Tafasitamab, Lenalidomide, and Rituximab for Patients with Relapsed or Refractory Follicular or Marginal Zone Lymphoma

Study of Tafasitamab, Lenalidomide, and Rituximab for Patients with Relapsed or Refractory Follicular or Marginal Zone Lymphoma

Study of Boserolimab, MK-0482, and Pembrolizumab for Patients with Advanced Non-Small Cell Lung Cancer Resistant to PD-(L)1 Therapy

Study of Boserolimab, MK-0482, and Pembrolizumab for Patients with Advanced Non-Small Cell Lung Cancer Resistant to PD-(L)1 Therapy

Study on Patient Preference for Nivolumab and Relatlimab Administration Methods in Melanoma Patients

Study on Patient Preference for Nivolumab and Relatlimab Administration Methods in Melanoma Patients

Study on the Effectiveness and Safety of Epcoritamab Alone or with Lenalidomide for Patients with Diffuse Large B-Cell Lymphoma Who Cannot Use Anthracyclines

Study of BMS-986315 and Nivolumab with Chemotherapy for First-line Treatment in Stage IV or Recurrent Non-Small Cell Lung Cancer Patients

Study of BMS-986315 and Nivolumab with Chemotherapy for First-line Treatment in Stage IV or Recurrent Non-Small Cell Lung Cancer Patients

Study of BMS-986466 with Adagrasib and Cetuximab for Patients with KRAS G12C-mutant Advanced Solid Tumors

Study of BMS-986466 with Adagrasib and Cetuximab for Patients with KRAS G12C-mutant Advanced Solid Tumors